Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Maximize Market Research Pvt. Ltd.AI in Clinical Trials Market to Reach USD 7.32 Billion by 2034 as AI Reshapes Patient Recruitment, Data Analysis and Drug Development, says Maximize Market ResearchThe Global AI in Clinical Trials Market was valued at USD 2 Billion in 2025 and is projected to grow at a 15.5% CAGR from 2026 to 2034, reaching USD 7.32 Billion by 2034, according to Maximize Market Research. Global AI in Clinical Trials Market...
- Kodiak Sciences Inc.Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular DegenerationKodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time — Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
- ArteraNew Data Highlight Artera's MMAI Consistency Across Diverse Patient Populations at ASTRO 2026SAN FRANCISCO, September 25, 2026--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will be featured in new data presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
- Quest PharmaTech Announces Change of Chief Executive OfficerQuest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be retiring from his position as Quest’s CEO. Dr. Madiyalakan has been the CEO of Quest since August 2006. Mr. Jeffrey Shon, a director of Quest, will be taking over the role of CEO. Mr. Shon has considerable experience in the areas of legal, regulatory and corporate affairs, including venture capital funding focused on emerging technologies.
- Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity DeficiencyCalidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American Company Guide (the "Company Guide")requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice also indicates that the Company is not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).
- The Biologics License ApplicationIfinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily WithdrawnTOKYO, September 25, 2026--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn.
- NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting AdjustmentsNervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced it will restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended June 30, 2026.
- BioAge Labs, Inc.BioAge Labs to Present at Upcoming Investor ConferencesBioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
- Crescent Biopharma Announces Grants of Inducement AwardsCrescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on September 24, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Adicet Bio, Inc.Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus NephritisREDWOOD CITY, Calif., September 25, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephriti
- CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th DeadlineIf you purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
- Baystate Health SystemBAYSTATE HEALTH ANNOUNCES PARTICIPATION IN NATIONAL CLINICAL TRIAL FOR ADVANCED BRAIN ANEURYSM TREATMENTFirst Hospital in the Country to Enroll Patients — Baystate Health announced today that it was selected to participate in a groundbreaking national clinical trial for Advanced Brain Aneurysm treatment and has enrolled the country's first...